Screener
Castle Biosciences CSTL Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating lease liabilities | (172) | (526) |
| Accrued compensation | (19,176) | (14,698) |
| Other accrued and current liabilities | 2,755 | 1,141 |
| Net cash used in operating activities | (22,129) | (6,036) |
| INVESTING ACTIVITIES | ||
| Purchases of marketable investment securities | (55,136) | (48,431) |
| Proceeds from maturities of marketable investment securities | 39,100 | 36,300 |
| Purchases of debt securities classified as held-to-maturity | — | (5,569) |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's operating cash flow?
- Castle Biosciences (CSTL) reported operating cash flow of -$22.13M in Q1 2026.
- How has Castle Biosciences's operating cash flow changed year-over-year?
- Castle Biosciences's operating cash flow decreased by 266.6% year-over-year, from -$6.04M to -$22.13M.
- What is the long-term trend for Castle Biosciences's operating cash flow?
- Over 3 years (2021 to 2025), Castle Biosciences's operating cash flow has grown at a 50.2% compound annual growth rate (CAGR), from -$18.98M to $64.35M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Castle Biosciences's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude